2
Clinical Trials associated with 64Cu-TR2205(C-Ray)A Prospective, Randomized, Open-label, Phase I Study of TRDC002 in the Diagnosis of Patients With PSMA-positive Recurrent or Metastatic Prostate Cancer
TRDC002 uses a radioactive form (64Cu) to trace the PSMA positive prostate cancer. The purpose of this study is to investigate TRDC002 as a PSMA PET tracer to localize PSMA positive lesions in adult patients with recurrent or metastatic prostate cancer. We plan to assess the PSMA PET/CT image quality following administration of two dose levels of TRDC002 to determine an acceptable dose and optimal acquisition time for obtaining diagnostic quality PET/CT images. The safety and tolerability, PK, biodistribution, dosimetry of TRDC002 will also be evaluated in this study.
/ RecruitingNot ApplicableIIT A comparative study on the kinetic parameters imaging and radiation dosimetry of different PSMA probes labeled with copper-64 in patients with prostate cancer
100 Clinical Results associated with 64Cu-TR2205(C-Ray)
100 Translational Medicine associated with 64Cu-TR2205(C-Ray)
100 Patents (Medical) associated with 64Cu-TR2205(C-Ray)
100 Deals associated with 64Cu-TR2205(C-Ray)